Literature DB >> 10202192

Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey.

C H Rojas-Fernandez1, G C Kephart, I S Sketris, K Kass.   

Abstract

OBJECTIVE: To determine current patterns of acetylsalicylic acid (ASA) use in Nova Scotia for individuals with self-reported myocardial infarction, stroke or ischemic heart disease.
DESIGN: Descriptive, cross-sectional, population-based study using data from the 1995 Nova Scotia Health Survey (NSHS). The NSHS was based on a probability sample and was representative of the Nova Scotia adult population by age, sex and region. Survey data were obtained by standardized home interviews conducted by trained public health nurses.
SETTING: The province of Nova Scotia in 1995. PARTICIPANTS: Survey respondents who reported having a myocardial infarction, stroke or ischemic heart disease were assessed.
RESULTS: Among those who reported a history of myocardial infarction, stroke or ischemic heart disease, 55% (95% CI 47% to 63%), 49% (95% CI 38% to 61%) and 54% (95% CI 39% to 68%), respectively, reported using ASA at the time of the survey. Overall, only 53% of those with cardiovascular disease were using ASA. Exclusion of persons with potential contraindications to ASA did not significantly increase these proportions.
CONCLUSIONS: ASA appears to be underused in those at high risk for future vascular events. Further research is required to investigate determinants of ASA use and to increase appropriate use of ASA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202192

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  4 in total

1.  Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke.

Authors:  E L L M De Schryver; J van Gijn; L J Kappelle; P J Koudstaal; A Algra
Journal:  J Neurol       Date:  2005-04-29       Impact factor: 4.849

2.  Clinical prognosis, pre-existing conditions and the use of reperfusion therapy for patients with ST segment elevation acute myocardial infarction.

Authors:  Andrea B Parker; C David Naylor; Alice Chong; David A Alter
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

3.  A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240].

Authors:  Finlay A McAlister; Miriam Fradette; Michelle Graham; Sumit R Majumdar; William A Ghali; Randall Williams; Ross T Tsuyuki; James McMeekin; Jeremy Grimshaw; Merril L Knudtson
Journal:  Implement Sci       Date:  2006-05-06       Impact factor: 7.327

4.  Evidence-based cardiovascular care in the community: a population-based cross-sectional study.

Authors:  Wayne Putnam; Frederick I Burge; Beverley Lawson; Jafna L Cox; Ingrid Sketris; Gordon Flowerdew; David Zitner
Journal:  BMC Fam Pract       Date:  2004-04-01       Impact factor: 2.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.